The notes provided in this article relate to two components
of the development of vaccines against schistosomiasis: (1) The
characteristics of schistosome infections (eg. features of the
schistosome life cycle), and the parasite itself, that have
implications for vaccination strategies; (2) The characteristics of the
biopharmaceutical industry that have implications for product development.
As will be seen, these two topic areas are not vastly disparate.
